Outsourced Pharma White Papers

  1. The Key To Accelerating RNA-LNP Drug Development 12/27/2023

    Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.

  2. CGMP-Validated RCL Assay Used For Release Testing Of Manufactured Viruses, Gene Mediated Cell Therapy Products 3/5/2025

    Ensure the safety and efficacy of lentiviral-based therapies by addressing the risks of replication-competent lentiviruses (RCLs) through advanced monitoring and control strategies.

  3. Regulatory Frameworks For mRNA Therapeutics 3/17/2025

    The RNA therapeutics and vaccines market has grown rapidly, driven by siRNA and mRNA technologies. Explore how these advancements are now being applied to cancer vaccines and innovative therapeutics.

  4. Streamlining Development: Advantages Of An All-In-One Solution 6/2/2025

    Antibody-drug conjugate (ADC) development requires tightly integrated manufacturing. Streamlined, end-to-end solutions reduce complexity, improve quality, and accelerate time-to-market.

  5. Pharmaceutical Spray Drying – Technology And Applications 1/21/2025

    Explore the transformative potential of pharmaceutical spray drying in improving drug formulation, bioavailability, and delivery through versatile and innovative applications.

  6. Tablet Manufacturing Technologies For Solid Drug Formulation 4/2/2025

    Compressed tablets are common oral solid dosages that contain the API and various excipients. Learn about the critical steps in selecting manufacturing methods and excipients to achieve the desired therapeutic effects and stability.

  7. Utilizing MAPPs For An Enhanced Assessment Of Immunogenicity 1/4/2024

    Explore how MAPPS demonstrates promise as a valuable tool for comprehensive immunogenicity assessment in therapeutic protein development, contributing to safer and more effective biologics.

  8. Quantitation Of Monoclonal Antibodies In Serum 2/8/2024

    Monoclonal antibodies (mAbs) are a rapidly growing group of targeted therapeutics. Gain insight into the importance of optimized bioanalytical assay platforms for mAb development.

  9. Maximizing rAAV Production Efficiency: Introducing Pro10™ Cell Line 3/13/2024

    This HEK293-derived, animal component-free suspension cell line forms the foundation of a scalable, robust platform process that accelerates AAV manufacturing.

  10. Safety, Containment, And Analysis Of Highly Potent Compounds 5/16/2024

    Explore a comprehensive overview of the challenges, requirements, and best practices for safely working with highly potent compounds in drug development and manufacturing.